Science News
from research organizations

Enzyme used in antidepressants could help researchers develop prostate cancer treatments

Date:
June 1, 2014
Source:
Cedars-Sinai Medical Center
Summary:
An enzyme commonly used as a target for antidepressants may also promote prostate cancer growth, an international team of scientists report. The study found that suppressing the enzyme monoamine oxidase A, or MAOA, may reduce or even eliminate prostate tumor growth and metastasis in laboratory mice. The finding could open the door for physicians to use antidepressants to fight prostate cancer. Currently, drugs that inhibit MAOA enzymes are used to treat patients with mental illnesses like depression.
Share:
       
FULL STORY

An international team of scientists including researchers at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and the University of Southern California found that an enzyme commonly used as a target for antidepressants may also promote prostate cancer growth.

The study, published in the Journal of Clinical Investigation, found that suppressing the enzyme monoamine oxidase A, or MAOA, may reduce or even eliminate prostate tumor growth and metastasis in laboratory mice. The finding could open the door for physicians to use antidepressants to fight prostate cancer. Currently, drugs that inhibit MAOA enzymes are used to treat patients with mental illnesses like depression.

"When this enzyme is not suppressed, it produces a tumor-rich environment that fuels the growth and metastasis of prostate cancer cells," said Leland Chung, PhD, corresponding author of the paper and director of the Uro-Oncology Research Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute. "Suppressing this enzyme and combining it with current therapies may provide a better way to manage and cure men with metastatic prostate cancer."

MAOA regulates the amount of neurotransmitters in the central nervous system by deactivating and breaking them down. Like all enzymes in the brain, MAOA is needed in optimum quantities to work effectively on patients. Previous studies have shown that too much MAOA is linked with depression, while too little of the enzyme is linked with autism, aggression and anxiety.

"This is the first paper showing that MAOA plays an important role in prostate cancer progression and metastasis and may provide an unmet need in cancer treatment," said Jean C. Shih, University Professor at the USC School of Pharmacy, two-time National Institutes of Health MERIT awardee and co-corresponding author of the study.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jason Boyang Wu, Chen Shao, Xiangyan Li, Qinlong Li, Peizhen Hu, Changhong Shi, Yang Li, Yi-Ting Chen, Fei Yin, Chun-Peng Liao, Bangyan L. Stiles, Haiyen E. Zhau, Jean C. Shih, Leland W.K. Chung. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis. Journal of Clinical Investigation, 2014; DOI: 10.1172/JCI70982

Cite This Page:

Cedars-Sinai Medical Center. "Enzyme used in antidepressants could help researchers develop prostate cancer treatments." ScienceDaily. ScienceDaily, 1 June 2014. <www.sciencedaily.com/releases/2014/06/140601113953.htm>.
Cedars-Sinai Medical Center. (2014, June 1). Enzyme used in antidepressants could help researchers develop prostate cancer treatments. ScienceDaily. Retrieved May 27, 2015 from www.sciencedaily.com/releases/2014/06/140601113953.htm
Cedars-Sinai Medical Center. "Enzyme used in antidepressants could help researchers develop prostate cancer treatments." ScienceDaily. www.sciencedaily.com/releases/2014/06/140601113953.htm (accessed May 27, 2015).

Share This Page: